Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEAR: Durvalumab with or without Ceralasertib in Adjuvant NSCLC
NCT06732401Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ceralasertib in non-small cell lung cancer (NSCLC), sponsored by National Cancer Institute. Started Aug 2025; status: active, not recruiting.
02
Drugs
ceralasertib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06732401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06732401.